Erratum: Codelivery of Sorafenib and Curcumin by Directed Self-Assembled Nanoparticles Enhances Therapeutic Effect on Hepatocellular Carcinoma (Molecular Pharmaceutics (2015) 12:3 (922?931) DOI: 10.1021/mp500755j);Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma

Molecular Pharmaceutics

Volumn 12, Issue 3, 2015, Pages 922-931

  Cao, Haiqiang ^a   Wang, Yixin ^a,b   He, Xinyu ^a   Zhang, Zhiwen ^a   Yin, Qi ^a   Chen, Yi ^a   Yu, Haijun ^a   Huang, Yongzhuo ^a   Chen, Lingli ^a   Xu, Minghua ^a   Gu, Wangwen ^a   Li, Yaping ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Codelivery; Curcumin; Hepatocellular carcinoma; Nanoparticles; Sorafenib

Indexed keywords

ALPHA TOCOPHEROL SUCCINATE; CURCUMIN; DIRECTED SELF ASSEMBLED NANOPARTICLE; MACROGOL DERIVATIVE; NANOCARRIER; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NANOPARTICLE; NICOTINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; GASTROINTESTINAL TRACT; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIGHT SCATTERING; LIVER CELL CARCINOMA; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SCREENING; LIVER NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHARMACEUTICS; TISSUE DISTRIBUTION; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOPHARMACEUTICS; CELL LINE, TUMOR; CELL PROLIFERATION; CURCUMIN; DRUG DELIVERY SYSTEMS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84924117472     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.9b01193     Document Type: Erratum

References (41)

1. El-Serag, H. B. Hepatocellular carcinoma N. Engl. J. Med. 2011, 365 (12) 1118-27
2. Singh, S.; Singh, P. P.; Roberts, L. R.; Sanchez, W. Chemopreventive strategies in hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. 2014, 11 (1) 45-54
3. Forner, A.; Llovet, J. M.; Bruix, J. Hepatocellular carcinoma Lancet 2012, 379 (9822) 1245-55
4. Asghar, U.; Meyer, T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J. Hepatol. 2012, 56 (3) 686-695
5. Llovet, J. M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Gane, E.; Blanc, J. F.; de Oliveira, A. C.; Santoro, A.; Raoul, J. L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T. F.; Galle, P. R.; Seitz, J. F.; Borbath, I.; Haussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J. Group, S. I. S. Sorafenib in advanced hepatocellular carcinoma N. Engl. J. Med. 2008, 359 (4) 378-90
6. Wilhelm, S. M.; Adnane, L.; Newell, P.; Villanueva, A.; Llovet, J. M.; Lynch, M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol. Cancer Ther. 2008, 7 (10) 3129-3140
7. Cheng, A. L.; Kang, Y. K.; Chen, Z.; Tsao, C. J.; Qin, S.; Kim, J. S.; Luo, R.; Feng, J.; Ye, S.; Yang, T. S.; Xu, J.; Sun, Y.; Liang, H.; Liu, J.; Wang, J.; Tak, W. Y.; Pan, H.; Burock, K.; Zou, J.; Voliotis, D.; Guan, Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial Lancet Oncol. 2009, 10 (1) 25-34
8. Shen, Y. C.; Ou, D. L.; Hsu, C.; Lin, K. L.; Chang, C. Y.; Lin, C. Y.; Liu, S. H.; Cheng, A. L. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma Br. J. Cancer 2013, 108 (1) 72-81
9. Siegel, A. B.; Olsen, S. K.; Magun, A.; Brown, R. S. Sorafenib: Where do we go from here? Hepatology 2010, 52 (1) 360-369
10. Lee, W. H.; Loo, C. Y.; Young, P. M.; Traini, D.; Mason, R. S.; Rohanizadeh, R. Recent advances in curcumin nanoformulation for cancer therapy Expert Opin. Drug Delivery 2014, 11 (8) 1183-201
11. Wilken, R.; Veena, M. S.; Wang, M. B.; Srivatsan, E. S. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma Mol. Cancer 2011, 10, 12
12. Wang, M.; Ruan, Y.; Chen, Q.; Li, S.; Wang, Q.; Cai, J. Curcumin induced HepG2 cell apoptosis-associated mitochondrial membrane potential and intracellular free Ca(2+) concentration Eur. J. Pharmacol. 2011, 650 (1) 41-7
13. Vandita, K.; Shashi, B.; Santosh, K. G.; Pal, K. I. Enhanced apoptotic effect of curcumin loaded solid lipid nanoparticles Mol. Pharmaceutics 2012, 9 (12) 3411-21
14. Sinha, D.; Biswas, J.; Sung, B.; Aggarwal, B. B.; Bishayee, A. Chemopreventive and chemotherapeutic potential of curcumin in breast cancer Curr. Drug Targets 2012, 13 (14) 1799-819
15. Shehzad, A.; Lee, J.; Lee, Y. S. Curcumin in various cancers BioFactors 2013, 39 (1) 56-68
16. Naksuriya, O.; Okonogi, S.; Schiffelers, R. M.; Hennink, W. E. Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment Biomaterials 2014, 35 (10) 3365-3383
17. Dhule, S. S.; Penfornis, P.; He, J.; Harris, M. R.; Terry, T.; John, V.; Pochampally, R. The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma Mol. Pharmaceutics 2014, 11 (2) 417-27
18. Boztas, A. O.; Karakuzu, O.; Galante, G.; Ugur, Z.; Kocabas, F.; Altuntas, C. Z.; Yazaydin, A. O. Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells Mol. Pharmaceutics 2013, 10 (7) 2676-83
19. Ganta, S.; Amiji, M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells Mol. Pharm. 2009, 6 (3) 928-39
20. Zhang, Z.; Niu, B.; Chen, J.; He, X.; Bao, X.; Zhu, J.; Yu, H.; Li, Y. The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer Biomaterials 2014, 35 (15) 4565-4572
21. Anand, P.; Kunnumakkara, A. B.; Newman, R. A.; Aggarwal, B. B. Bioavailability of curcumin: problems and promises Mol.Pharm. 2007, 4 (6) 807-18
22. Wei, X.; Senanayake, T. H.; Bohling, A.; Vinogradov, S. V. Targeted nanogel conjugate for improved stability and cellular permeability of curcumin: synthesis, pharmacokinetics, and tumor growth inhibition Mol. Pharmaceutics 2014, 11 (9) 3112-22
23. Ma, L.; Kohli, M.; Smith, A. Nanoparticles for combination drug therapy ACS Nano 2013, 7 (11) 9518-25
24. Zhao, Y.; Thorkelsson, K.; Mastroianni, A. J.; Schilling, T.; Luther, J. M.; Rancatore, B. J.; Matsunaga, K.; Jinnai, H.; Wu, Y.; Poulsen, D.; Frechet, J. M. J.; Alivisatos, A. P.; Xu, T. Small-molecule-directed nanoparticle assembly towards stimuli-responsive nanocomposites Nat. Mater. 2009, 8 (12) 979-985
25. Zhang, Z.; Cao, H.; Jiang, S.; Liu, Z.; He, X.; Yu, H.; Li, Y. Nanoassembly of probucol enables novel therapeutic efficacy in the suppression of lung metastasis of breast cancer Small 2014, 10 (22) 4735-45
26. Grzelczak, M.; Vermant, J.; Furst, E. M.; Liz-Marzan, L. M. Directed self-assembly of nanoparticles ACS Nano 2010, 4 (7) 3591-605
27. Sanchez-Iglesias, A.; Grzelczak, M.; Altantzis, T.; Goris, B.; Perez-Juste, J.; Bals, S.; Van Tendeloo, G.; Donaldson, S. H.; Chmelka, B. F.; Israelachvili, J. N.; Liz-Marzan, L. M. Hydrophobic interactions modulate self-assembly of nanoparticles ACS Nano 2012, 6 (12) 11059-11065
28. Wang, W.; Chau, Y. Efficient and facile formation of two-component nanoparticles via aromatic moiety directed self-assembly Chem. Commun. 2011, 47 (37) 10224-6
29. Zhang, Z.; Jiang, S.; Liu, Z.; Niu, B.; Gu, W.; Li, Y.; Cui, J. Directed self-assembled nanoparticles of probucol improve oral delivery: fabrication, performance and correlation Pharm. Res. 2014, 31 (9) 2266-75
30. Xiao, J.; Duan, X.; Yin, Q.; Miao, Z.; Yu, H.; Chen, C.; Zhang, Z.; Wang, J.; Li, Y. The inhibition of metastasis and growth of breast cancer by blocking the NF-κB signaling pathway using bioreducible PEI-based/p65 shRNA complex nanoparticles Biomaterials 2013, 34 (21) 5381-5390
31. Baker, M.; Robinson, S. D.; Lechertier, T.; Barber, P. R.; Tavora, B.; D'Amico, G.; Jones, D. T.; Vojnovic, B.; Hodivala-Dilke, K. Use of the mouse aortic ring assay to study angiogenesis Nat. Protoc. 2012, 7 (1) 89-104
32. Shen, J.; Sun, H.; Meng, Q.; Yin, Q.; Zhang, Z.; Yu, H.; Li, Y. Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA Mol. Pharmaceutics 2014, 11 (10) 3342-51
33. Zhang, Z.; Liu, Z.; Ma, L.; Jiang, S.; Wang, Y.; Yu, H.; Yin, Q.; Cui, J.; Li, Y. Reversal of multidrug resistance by mitochondrial targeted self-assembled nanocarrier based on stearylamine Mol. Pharmaceutics 2013, 10 (6) 2426-34
34. Markovsky, E.; Baabur-Cohen, H.; Satchi-Fainaro, R. Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs J. Controlled Release 2014, 187 (0) 145-157
35. Swarnakar, N. K.; Thanki, K.; Jain, S. Enhanced antitumor efficacy and counterfeited cardiotoxicity of combinatorial oral therapy using Doxorubicin- and Coenzyme Q10-liquid crystalline nanoparticles in comparison with intravenous Adriamycin Nanomed. NBM 2014, 10 (6) 1231-1241
36. Mi, Y.; Zhao, J.; Feng, S. S. Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer J. Controlled Release 2013, 169 (3) 185-92
37. Mishra, G. P.; Nguyen, D.; Alani, A. W. Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade Mol.Pharm. 2013, 10 (5) 2071-8
38. Zhang, Z.; Ma, L.; Jiang, S.; Liu, Z.; Huang, J.; Chen, L.; Yu, H.; Li, Y. A self-assembled nanocarrier loading teniposide improves the oral delivery and drug concentration in tumor J. Controlled Release 2013, 166 (1) 30-7
39. Gao, F.; Zhang, Z. W.; Bu, H. H.; Huang, Y.; Gao, Z. W.; Shen, J. N.; Zhao, C. J.; Li, Y. P. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism J. Controlled Release 2011, 149 (2) 168-174
40. Richly, H.; Schultheis, B.; Adamietz, I. A.; Kupsch, P.; Grubert, M.; Hilger, R. A.; Ludwig, M.; Brendel, E.; Christensen, O.; Strumberg, D. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial Eur. J. Cancer 2009, 45 (4) 579-87
41. Abou-Alfa, G. K.; Johnson, P.; Knox, J. J.; Capanu, M.; Davidenko, I.; Lacava, J.; Leung, T.; Gansukh, B.; Saltz, L. B. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial JAMA 2010, 304 (19) 2154-60